stoxline Quote Chart Rank Option Currency Glossary
Artelo Biosciences, Inc. (ARTL)
1.315  0.035 (2.73%)    04-19 16:00
Open: 1.3
High: 1.39
Volume: 5,460
Pre. Close: 1.28
Low: 1.2835
Market Cap: 4(M)
Technical analysis
2024-04-19 5:07:49 PM
Short term     
Mid term     
Targets 6-month :  1.79 1-year :  1.98
Resists First :  1.53 Second :  1.7
Pivot price 1.48
Supports First :  1.27 Second :  1.06
MAs MA(5) :  1.35 MA(20) :  1.48
MA(100) :  1.45 MA(250) :  1.61
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  6.3 D(3) :  9.9
RSI RSI(14): 34.2
52-week High :  2.98 Low :  1.14
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ARTL ] has closed above bottom band by 7.7%. Bollinger Bands are 75% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.39 - 1.4 1.4 - 1.41
Low: 1.26 - 1.27 1.27 - 1.28
Close: 1.3 - 1.32 1.32 - 1.33
Company Description

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Headline News

Mon, 25 Mar 2024
ARTL Stock Earnings: Artelo Biosciences Misses EPS for Q4 2023 - InvestorPlace

Tue, 12 Mar 2024
Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge - Yahoo Finance

Fri, 08 Sep 2023
Artelo plans IND filing for FABP5 inhibitor ART-26.12 for neuropathic pain following FDA guidance - BioWorld Online

Wed, 08 Dec 2021
Artelo Biosciences Inc. (NASDAQ: ARTL) Announce Fiscal Year 2021 Results And Updates On ART27.13 Study - BP Journal

Fri, 12 Feb 2021
ARTL Stock Alert: The Big Reason Biopharma Artelo Biosciences Is Rocketing Today - Yahoo Finance

Wed, 29 Jul 2020
Artelo Biosciences Inc (NASDAQ:ARTL) Posts Net Loss Of $951395 In Q3 2020 - BP Journal

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 3 (M)
Shares Float 3 (M)
Held by Insiders 0.8 (%)
Held by Institutions 0.7 (%)
Shares Short 15 (K)
Shares Short P.Month 19 (K)
Stock Financials
EPS -3.15
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.68
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -37.1 %
Return on Equity (ttm) -59.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -8 (M)
Levered Free Cash Flow -5 (M)
Stock Valuations
PE Ratio -0.42
PEG Ratio 0
Price to Book value 0.35
Price to Sales 0
Price to Cash Flow -0.52
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android